ABSTRACT
Background In response to the COVID-19 pandemic, some countries in the Asia-Pacific Region used very intensive control measures, and one of these, New Zealand (NZ), adopted a clear “elimination strategy”. We therefore aimed to compare key health and economic outcomes of NZ relative to OECD countries as of mid-June 2021.
Methods This analysis compared health outcomes (cumulative death rates from COVID-19 and “excess death” rates) and economic measures (quarterly GDP and unemployment levels) across OECD countries.
Results NZ had the lowest cumulative COVID-19 death rate in the OECD at 242 times lower than the 38-OECD-country average: 5·2 vs 1256 per million population. When considering “excess deaths”, NZ had the largest negative value in the OECD, equivalent to around 2000 fewer deaths than expected. When considering the average GDP change over the five quarters of 2020 to 2021-Q1, NZ was the sixth best performer (at 0·5% vs -0·3% for the OECD average). The increase in unemployment in NZ was also less than the OECD average (1·1 percentage points to a peak of 5·2%, vs 3·3 points to 8·6%, respectively).
Conclusions New Zealand’s elimination strategy response to COVID-19 produced the best mortality protection outcomes in the OECD. In economic terms it also performed better than the OECD average in terms of adverse impacts on GDP and employment. Nevertheless, a fuller accounting of the benefits and costs needs to be done once the population is vaccinated and longer-term health and economic outcomes are considered.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MB acknowledges funding support from the Health Research Council of New Zealand (20/1066). Nil for others.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Nil required for this analysis of high-level data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in the analysis is all available from public sources. Nevertheless, the relevant Excel spreadsheets are all available on request.
